Related Experiment Videos
Compliance to longterm vasoactive intracavernous therapy
A Pagliarulo1, G M Ludovico, E Cirillo-Marucco
1Cattedra e Divisione di Urologia, Università degli Studi di Bari, Italy.
International Journal of Impotence Research
|June 1, 1996
Summary
Intracavernous papaverine therapy for organic impotence showed low compliance, with over 40% of patients withdrawing early. Unsatisfaction and complications like hematomas and fibrosis were key reasons for discontinuing this erectile dysfunction treatment.
Area of Science:
- Urology
- Andrology
- Pharmacology
Background:
- Organic impotence affects a significant patient population.
- Intracavernous pharmacological therapy is a treatment option for erectile dysfunction.
- Papaverine has been used for intracavernous injections.
Purpose of the Study:
- To analyze the reasons for low compliance in patients undergoing intracavernous papaverine therapy for organic impotence.
- To evaluate the efficacy and complications of papaverine self-injection therapy.
Main Methods:
- A cohort of 107 patients with organic impotence were advised intracavernous papaverine therapy.
- 91 patients underwent self-injection after dose determination.
- Follow-up ranged from 30 to 90 months.
Main Results:
- 37 patients (40.7%) withdrew treatment within 3 months.
- Primary reasons for withdrawal included dissatisfaction (25.3%) and complications.
- Reported complications included local hematomas (42.6%), prolonged erections (11.1%), and penile fibrosis (16.7%).
Conclusions:
- Intracavernous papaverine therapy for organic impotence is associated with significant compliance issues.
- Patient dissatisfaction and treatment-related complications are major factors contributing to withdrawal.
- Alternative or improved therapeutic strategies may be needed to enhance compliance for erectile dysfunction management.